Pet Healthcare Spending Is Outpacing Human Healthcare Inflation — and Diagnostics Is Leading the Surge

The Humanisation of Pets Has Created a New Diagnostic Spending Category

American Pet Products Association data for 2025 put US pet industry expenditure at USD 157 billion, with veterinary care and products representing approximately USD 38 billion of that total. The compound annual growth rate of veterinary expenditure has outpaced general consumer spending growth consistently since 2015, and the diagnostic sub-segment has grown faster than veterinary care overall. The driver is a demographic and attitudinal shift: pet owners , particularly millennials and Gen Z, who are now the largest demographic cohort of pet-owning adults , treat companion animals as family members and are increasingly willing to authorise diagnostic workups, imaging, and specialty referrals that were historically associated with human medicine rather than veterinary practice.

The economic consequence is that veterinary diagnostics has become one of the most attractive sub-segments in the broader life sciences market. IDEXX Laboratories, which dominates in-clinic chemistry analysers, haematology equipment, and reference laboratory services, has delivered compound revenue growth of approximately 12 percent per year for a decade. Zoetis's diagnostics segment, built largely through acquisitions including Abaxis and the Smartbow livestock monitoring business, is the second largest player and growing faster than the parent company's pharmaceutical business. Heska Corporation, now part of Mars Petcare's veterinary diagnostics portfolio, focuses specifically on point-of-care haematology and immunoassay systems for independent veterinary practices.

Point-of-Care Testing Is Compressing the Diagnostic Cycle From Days to Minutes

The reference laboratory model , ship samples to a centralised lab, wait 24-to-48 hours for results , is structurally challenged by the introduction of high-quality in-clinic analysers capable of delivering complete blood counts, chemistry panels, and urinalysis results within 10-to-15 minutes. IDEXX's Catalyst One and ProCyte One systems, which run on a lease-and-consumables model analogous to inkjet printers, have driven the shift from send-out to in-clinic testing across practices with sufficient volume to justify the capital equipment. The business model implication is significant: practices retaining diagnostic revenue in-clinic rather than routing it through reference laboratories retain 3-to-4 times the revenue per test, at the cost of managing reagent inventory and instrument maintenance.

The adoption of in-clinic point-of-care testing has progressed fastest in corporate veterinary group practices, which have the scale to negotiate equipment lease terms, train staff consistently, and track diagnostic yield metrics across a portfolio of clinics. National Veterinary Associates, VetCor, and Banfield Pet Hospital , all owned by Mars Petcare , operate standardised diagnostic protocols across thousands of locations, and their purchasing power has accelerated equipment deployment at a pace that independent practices cannot match. The consolidation of the US veterinary practice market, where corporate groups now own approximately 30 percent of practices by count and a larger share by revenue, is creating a bifurcated diagnostic market between well-equipped corporate practices and independent clinics still relying on reference laboratory services for the majority of their diagnostic volume.

Molecular Diagnostics Is the Next Frontier , Infectious Disease Testing Is Already Here

The COVID-19 pandemic's acceleration of PCR testing infrastructure in human medicine had direct spillover effects into veterinary molecular diagnostics. IDEXX's RealPCR platform, which had been commercially available for infectious disease panels in veterinary medicine since before the pandemic, saw dramatically accelerated adoption as veterinary practitioners became familiar with PCR concepts and as manufacturers reduced per-test costs through higher reagent volumes. The platform now offers panels for canine infectious respiratory disease complex, equine respiratory pathogens, and feline upper respiratory infections that can deliver same-day results from in-clinic sample collection.

The molecular diagnostic frontier is expanding into oncology. Liquid biopsy technology , detecting circulating tumour DNA in blood samples , has moved from research application to commercial product in veterinary oncology faster than the equivalent human medicine transition. Volition's canine cancer detection test, which uses nucleosome profiling to identify cancer-associated chromatin signatures in blood, received regulatory clearance in 2024 and is now available through major US reference laboratory networks. PetDx's OncoK9 assay detects 30 cancer types from a blood draw in dogs, and the company has reported clinical sensitivity data suggesting the assay can detect cancer at earlier stages than conventional radiographic diagnosis in several cancer types. The oncology diagnostic segment is estimated to be a USD 2 billion opportunity in companion animal medicine by 2030.

Wearables and Remote Monitoring Are Creating Continuous Diagnostic Data Streams

The consumer wearable technology paradigm , continuous biometric monitoring with cloud-based analysis and alert generation , is being translated directly into companion animal health monitoring. PetPace's smart collar, Whistle Health's GPS and activity monitor, and Fi's smart dog collar all collect activity, sleep, and physiological data that can flag deviations from baseline patterns suggestive of pain, metabolic change, or early disease. Mars Petcare's Whistle business reports that the activity decline signature associated with osteoarthritis onset in dogs is detectable in collar data weeks before owners report observable lameness , a detection window that has direct clinical value for early intervention.

Veterinary practices are beginning to integrate wearable data into clinical workflows. Shepherd Veterinary Software has built integrations with Whistle and PetPace that surface trend data in the patient record interface, allowing practitioners to correlate owner-reported symptoms with objective activity and physiological data collected outside the clinic. The data generated by these devices is also creating new research assets: Mars Petcare's Dog Aging Project uses longitudinal wearable data from thousands of enrolled dogs to study the genetics and environmental factors underlying lifespan and healthspan in companion animals. The research application is generating publication output that validates the diagnostic utility of wearable data, which in turn supports the commercial argument for wearable adoption in clinical practice.

Insurance Penetration Is the Demand Accelerant That Converts Willing Into Paying Customers

Pet insurance penetration in the United States remains below 4 percent of the insured pet population, compared with above 25 percent in Sweden and above 15 percent in the United Kingdom. The gap represents both the immaturity of the US market and its growth potential: every percentage point of penetration growth represents millions of additional pets whose diagnostic and treatment costs are backstopped by insurance rather than owner out-of-pocket capacity. Trupanion, the market-leading US pet insurer by earned premium, has built its business model around direct integration with veterinary practice management software, enabling real-time insurance claim adjudication at the point of treatment rather than post-payment reimbursement. This frictionless claims experience removes the largest single barrier to pet insurance adoption , the reimbursement lag that discourages pet owners from purchasing coverage they will need to spend money upfront to use.

The entry of Nationwide, Lemonade, and Spot Insurance into the US pet insurance market has brought consumer marketing investment and digital distribution capability that specialist players like Trupanion and ASPCA Pet Health Insurance could not match alone. The combined effect of increased marketing, simplified digital enrolment, and employer-sponsored pet insurance benefits , which are now offered by over 7,500 US employers according to SHRM data , is accelerating enrolment growth at a rate that will materially expand the diagnostics-eligible pet population over the next decade. For IDEXX Laboratories and Zoetis, rising insurance penetration is a demand multiplier: insured pets visit veterinarians more frequently, authorise more diagnostic tests, and proceed to treatment at higher rates than uninsured pets whose owners face uncapped out-of-pocket exposure.

Top 10 Companies in the Global Veterinary Diagnostics Market

1. IDEXX Laboratories , Market leader in in-clinic veterinary analysers, reference laboratory services, and digital practice management software globally
2. Zoetis , Animal health pharmaceutical and diagnostics company with Abaxis point-of-care analysers and Smartbow livestock monitoring technology
3. Heska Corporation (Mars Petcare) , In-clinic haematology and immunoassay analyser specialist for companion animal veterinary practices, now within Mars Petcare portfolio
4. Antech Diagnostics (Mars Petcare) , US and international veterinary reference laboratory network operating alongside Mars Petcare's VCA hospital chain
5. Biomedical Systems (VetScan) , Point-of-care chemistry analyser manufacturer serving companion animal and large animal veterinary markets
6. PetDx , Liquid biopsy oncology diagnostics company with OncoK9 assay detecting 30 cancer types from a blood draw in dogs
7. Volition , Nucleosome profiling diagnostics company with canine cancer detection test cleared in 2024 and available through reference lab networks
8. Trupanion , US market-leading pet insurer with direct practice management system integration enabling real-time insurance adjudication at the point of care
9. Virbac , French animal health company with diagnostics, vaccines, and pharmaceuticals across companion animal and production animal markets
10. Elanco Animal Health , US animal health company with diagnostics and pharmaceutical products spanning companion animal and food animal segments